Evaluating the effectiveness of a new RSV vaccine for mothers and infants
Real-World Effectiveness of Maternal RSV Vaccination
This study is looking at how well a new RSV vaccine given to pregnant women works to protect their babies from RSV infections, especially when combined with other treatments, so that doctors and parents can make the best choices for keeping infants healthy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11120644 on NIH RePORTER |
What this research studies
This research investigates the real-world effectiveness of a newly licensed RSV vaccine administered to pregnant women. The study aims to understand how well the vaccine prevents respiratory syncytial virus (RSV) infections in infants, particularly in the context of other treatments like monoclonal antibodies. By analyzing data from various settings, the research will assess the vaccine's performance outside of clinical trials, considering factors such as the timing of administration and concurrent treatments. This information will help inform healthcare providers and parents about the best preventive measures against RSV.
Who could benefit from this research
Good fit: Ideal candidates for this research include pregnant women who are between 32 and 36 weeks of gestation and their infants.
Not a fit: Patients who are not pregnant or whose infants are older than 8 months may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of RSV-related illnesses and deaths in infants.
How similar studies have performed: Previous research has shown promising results with similar vaccine approaches, indicating potential for success in this area.
Where this research is happening
San Francisco, United States
- University of San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Regan, Annette Karena — University of San Francisco
- Study coordinator: Regan, Annette Karena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.